Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
Active, not recruiting · NCT05114421 · Registry updated 2026-08-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients | High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Peritoneal High Grade Serous Adenocarcinoma; Recurrent High Grade Fallopian Tube Serous Adenocarcinoma; Recurrent High Grade Ovarian Serous Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma | Active, not recruiting | Phase 2 | 2026-08-10 | NCT05114421 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| M.D. Anderson Cancer Center | 1145 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| M D Anderson Cancer Center | Houston | United States | 667 |